Clinical Trial Update: Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine [Phase 1]

View source ↗

Summary

Phase 1 trial updating safety, tolerability, and drug–drug interaction of ubrogepant with erenumab or galcanezumab in migraine patients; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Galcanezumab (galcanezumab)
• Ubrogepant (ubrogepant)
• erenumab (erenumab)

Snippet

Sponsor: Allergan | Conditions: Migraine | Phase 1 | Status: COMPLETED | Results posted: 2021-03-10